{"id":19165,"date":"2024-05-04T15:39:27","date_gmt":"2024-05-04T19:39:27","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=19165"},"modified":"2025-01-29T09:23:02","modified_gmt":"2025-01-29T14:23:02","slug":"sentynl","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/pt\/2024\/05\/04\/sentynl\/","title":{"rendered":"PRF agora colabora com Sentynl Therapeutics, nova propriet\u00e1ria global do tratamento com lonafarnib (Zokinvy\u00a9)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/static1.squarespace.webp&#8221; title_text=&#8221;static1.squarespace&#8221; url=&#8221;https:\/\/www.charitynavigator.org\/ein\/043460220&#8243; align=&#8221;center&#8221; admin_label=&#8221;Sentynl&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; width=&#8221;50%&#8221; max_width=&#8221;50%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.24.3&#8243; text_font_size=&#8221;18px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Effective Friday, May 3<sup>rd<\/sup>, 2024, <a href=\"https:\/\/url2.mailanyone.net\/scanner?m=1rzcKM-0009Dy-3G&amp;d=4%7Cmail%2F90%2F1713963600%2F1rzcKM-0009Dy-3G%7Cin2m%7C57e1b682%7C18374732%7C14629442%7C662903CE3D97FA99FA9E3F52842D032F&amp;o=%2Fphte%3A%2Fstsonnt%2F.cmyl&amp;s=pj636_P9eRvPUtyP8VtSjuVNKfg\">Sentynl Therapeutics, Inc.<\/a> (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd, has acquired global rights to lonafarnib (Zokinvy) from Eiger BioPharmaceuticals (Eiger). Zokinvy\u00ae is provided to families worldwide who are using the drug as a treatment for progeria.<\/p>\n<p>Based in San Diego, California, Sentynl is focused on providing novel biopharmaceutical medicines that extend, improve, or enhance the lives of people with rare disease (https:\/\/sentynl.com\/). PRF is thankful for the successful partnership with Eiger, and excited to now join forces with Sentynl. PRF will work closely with them, as we did with Eiger, to assist in the company\u2019s efforts to ensure uninterrupted supply of Zokinvy for patients around the world.\u00a0\u00a0<\/p>\n<p>A link to Sentynl\u2019s press release on this news can be found <a href=\"https:\/\/www.prnewswire.com\/news-releases\/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html\">here<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A partir de sexta-feira, 3 de maio, a Sentynl Therapeutics ser\u00e1 respons\u00e1vel pela fabrica\u00e7\u00e3o e distribui\u00e7\u00e3o do Zokinvy, o tratamento aprovado pela FDA para Prog\u00e9ria. <\/p>","protected":false},"author":2,"featured_media":18808,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-19165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sentynl I The Progeria esearch Foundation<\/title>\n<meta name=\"description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/pt\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sentynl I The Progeria esearch Foundation\" \/>\n<meta property=\"og:description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/pt\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-04T19:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T14:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/sentynl-square-logo.jpeg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/\",\"name\":\"Sentynl I The Progeria esearch Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/sentynl-square-logo.jpeg\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"description\":\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/sentynl-square-logo.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/sentynl-square-logo.jpeg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/2024\\\/05\\\/04\\\/sentynl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.progeriaresearch.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ProgeriaResearch\\\/\",\"https:\\\/\\\/x.com\\\/Progeria\",\"https:\\\/\\\/www.instagram.com\\\/progeriaresearch\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/pt\\\/author\\\/karenb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sentynl I The Progeria esearch Foundation","description":"A partir de sexta-feira, 3 de maio, a Sentynl Therapeutics ser\u00e1 respons\u00e1vel pela fabrica\u00e7\u00e3o e distribui\u00e7\u00e3o do Zokinvy, o tratamento aprovado pela FDA para Prog\u00e9ria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/pt\/2024\/05\/04\/sentynl\/","og_locale":"pt_PT","og_type":"article","og_title":"Sentynl I The Progeria esearch Foundation","og_description":"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/pt\/2024\/05\/04\/sentynl\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2024-05-04T19:39:27+00:00","article_modified_time":"2025-01-29T14:23:02+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"wordCount":266,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","articleSection":["News","Uncategorized"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","url":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","name":"Sentynl I The Progeria esearch Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","description":"A partir de sexta-feira, 3 de maio, a Sentynl Therapeutics ser\u00e1 respons\u00e1vel pela fabrica\u00e7\u00e3o e distribui\u00e7\u00e3o do Zokinvy, o tratamento aprovado pela FDA para Prog\u00e9ria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Funda\u00e7\u00e3o de Pesquisa Progeria","description":"Pelas Crian\u00e7as \u2665 Pela Cura","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Funda\u00e7\u00e3o de Pesquisa Progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/pt\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/posts\/19165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/comments?post=19165"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/posts\/19165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/media\/18808"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/media?parent=19165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/categories?post=19165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/pt\/wp-json\/wp\/v2\/tags?post=19165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}